242 related articles for article (PubMed ID: 27891815)
1. Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.
Müller A; Jurcoane A; Kebir S; Ditter P; Schrader F; Herrlinger U; Tzaridis T; Mädler B; Schild HH; Glas M; Hattingen E
Cancer Med; 2017 Jan; 6(1):89-99. PubMed ID: 27891815
[TBL] [Abstract][Full Text] [Related]
2. Quantitative T1 mapping indicates tumor infiltration beyond the enhancing part of glioblastomas.
Nöth U; Tichy J; Tritt S; Bähr O; Deichmann R; Hattingen E
NMR Biomed; 2020 Mar; 33(3):e4242. PubMed ID: 31880005
[TBL] [Abstract][Full Text] [Related]
3. Value of quantitative magnetic resonance imaging T1-relaxometry in predicting contrast-enhancement in glioblastoma patients.
Hattingen E; Müller A; Jurcoane A; Mädler B; Ditter P; Schild H; Herrlinger U; Glas M; Kebir S
Oncotarget; 2017 Aug; 8(32):53542-53551. PubMed ID: 28881830
[TBL] [Abstract][Full Text] [Related]
4. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
[TBL] [Abstract][Full Text] [Related]
5. Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study.
Pérez-Beteta J; Martínez-González A; Molina D; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; López C; Claramonte M; Barcia JA; Iglesias L; Avecillas J; Albillo D; Navarro M; Villanueva JM; Paniagua JC; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Delgado MD; Del Valle A; Falkov A; Schucht P; Arana E; Pérez-Romasanta L; Pérez-García VM
Eur Radiol; 2017 Mar; 27(3):1096-1104. PubMed ID: 27329522
[TBL] [Abstract][Full Text] [Related]
6. Prognosis prediction of measurable enhancing lesion after completion of standard concomitant chemoradiotherapy and adjuvant temozolomide in glioblastoma patients: application of dynamic susceptibility contrast perfusion and diffusion-weighted imaging.
Kim JH; Choi SH; Ryoo I; Yun TJ; Kim TM; Lee SH; Park CK; Kim JH; Sohn CH; Park SH; Kim IH
PLoS One; 2014; 9(11):e113587. PubMed ID: 25419975
[TBL] [Abstract][Full Text] [Related]
7. Quantitative T1 and T2 mapping in recurrent glioblastomas under bevacizumab: earlier detection of tumor progression compared to conventional MRI.
Lescher S; Jurcoane A; Veit A; Bähr O; Deichmann R; Hattingen E
Neuroradiology; 2015 Jan; 57(1):11-20. PubMed ID: 25287076
[TBL] [Abstract][Full Text] [Related]
8. Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma.
Ingrisch M; Schneider MJ; Nörenberg D; Negrao de Figueiredo G; Maier-Hein K; Suchorska B; Schüller U; Albert N; Brückmann H; Reiser M; Tonn JC; Ertl-Wagner B
Invest Radiol; 2017 Jun; 52(6):360-366. PubMed ID: 28079702
[TBL] [Abstract][Full Text] [Related]
9. MR Imaging Analysis of Non-Measurable Enhancing Lesions Newly Appearing after Concomitant Chemoradiotherapy in Glioblastoma Patients for Prognosis Prediction.
Kim BR; Choi SH; Yun TJ; Lee ST; Park CK; Kim TM; Kim JH; Park SW; Sohn CH; Park SH; Kim IH
PLoS One; 2016; 11(11):e0166096. PubMed ID: 27835666
[TBL] [Abstract][Full Text] [Related]
10. Robust texture features for response monitoring of glioblastoma multiforme on T1-weighted and T2-FLAIR MR images: a preliminary investigation in terms of identification and segmentation.
Assefa D; Keller H; Ménard C; Laperriere N; Ferrari RJ; Yeung I
Med Phys; 2010 Apr; 37(4):1722-36. PubMed ID: 20443493
[TBL] [Abstract][Full Text] [Related]
11. Response Assessment in Neuro-Oncology criteria, contrast enhancement and perfusion MRI for assessing progression in glioblastoma.
Tensaouti F; Khalifa J; Lusque A; Plas B; Lotterie JA; Berry I; Laprie A; Cohen-Jonathan Moyal E; Lubrano V
Neuroradiology; 2017 Oct; 59(10):1013-1020. PubMed ID: 28842741
[TBL] [Abstract][Full Text] [Related]
12. The effect of glioblastoma heterogeneity on survival stratification: a multimodal MR imaging texture analysis.
Liu Y; Zhang X; Feng N; Yin L; He Y; Xu X; Lu H
Acta Radiol; 2018 Oct; 59(10):1239-1246. PubMed ID: 29430935
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.
Wick W; Chinot OL; Bendszus M; Mason W; Henriksson R; Saran F; Nishikawa R; Revil C; Kerloeguen Y; Cloughesy T
Neuro Oncol; 2016 Oct; 18(10):1434-41. PubMed ID: 27515827
[TBL] [Abstract][Full Text] [Related]
14. Effect of contrast agent dosage on longitudinal relaxation time, signal and apparent tumor volume in glioblastoma at 9.4T.
Nickel A; Milford D; Fischer M; Bendszus M; Heiland S
Z Med Phys; 2019 Aug; 29(3):206-215. PubMed ID: 30470504
[TBL] [Abstract][Full Text] [Related]
15. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
[TBL] [Abstract][Full Text] [Related]
16. Comparison between the Prebolus T1 Measurement and the Fixed T1 Value in Dynamic Contrast-Enhanced MR Imaging for the Differentiation of True Progression from Pseudoprogression in Glioblastoma Treated with Concurrent Radiation Therapy and Temozolomide Chemotherapy.
Nam JG; Kang KM; Choi SH; Lim WH; Yoo RE; Kim JH; Yun TJ; Sohn CH
AJNR Am J Neuroradiol; 2017 Dec; 38(12):2243-2250. PubMed ID: 29074633
[TBL] [Abstract][Full Text] [Related]
17. Dynamic contrast-enhanced MR imaging in predicting progression of enhancing lesions persisting after standard treatment in glioblastoma patients: a prospective study.
Yoo RE; Choi SH; Kim TM; Park CK; Park SH; Won JK; Kim IH; Lee ST; Choi HJ; You SH; Kang KM; Yun TJ; Kim JH; Sohn CH
Eur Radiol; 2017 Aug; 27(8):3156-3166. PubMed ID: 27975145
[TBL] [Abstract][Full Text] [Related]
18. Early changes in perfusion of glioblastoma during radio- and chemotherapy evaluated by T1-dynamic contrast enhanced magnetic resonance imaging.
Møller S; Lundemann M; Law I; Poulsen HS; Larsson HB; Engelholm SA
Acta Oncol; 2015; 54(9):1521-8. PubMed ID: 26203926
[TBL] [Abstract][Full Text] [Related]
19. Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study.
Jayachandran Preetha C; Meredig H; Brugnara G; Mahmutoglu MA; Foltyn M; Isensee F; Kessler T; Pflüger I; Schell M; Neuberger U; Petersen J; Wick A; Heiland S; Debus J; Platten M; Idbaih A; Brandes AA; Winkler F; van den Bent MJ; Nabors B; Stupp R; Maier-Hein KH; Gorlia T; Tonn JC; Weller M; Wick W; Bendszus M; Vollmuth P
Lancet Digit Health; 2021 Dec; 3(12):e784-e794. PubMed ID: 34688602
[TBL] [Abstract][Full Text] [Related]
20. Automated Volumetric Analysis of Postoperative Magnetic Resonance Imaging Predicts Survival in Patients with Glioblastoma.
Krivoshapkin AL; Sergeev GS; Gaytan AS; Kalneus LE; Kurbatov VP; Abdullaev OA; Salim N; Bulanov DV; Simonovich AE
World Neurosurg; 2019 Jun; 126():e1510-e1517. PubMed ID: 30910753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
